(Q35637987)

9 August 2017

1 reference

title

Teriparatide for severe osteoporosis (English)

1 reference

9 August 2017

0 references

Kimberly A Cappuzzo

1 reference

9 August 2017

Jeffrey C Delafuente

series ordinal

1 reference

9 August 2017

language of work or name

English

0 references

publication date

30 December 2003

1 reference

Annals of Pharmacotherapy

9 August 2017

published in

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

294-302

1 reference

Developments in parathyroid hormone and related peptides as bone-formation agents

9 August 2017

cites work

1 reference

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

21 January 2018

1 reference

Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques

21 January 2018

1 reference

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

21 January 2018

1 reference

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

21 January 2018

1 reference

Role of osteoblasts in hormonal control of bone resorption—A hypothesis

21 January 2018

1 reference

New anabolic therapies in osteoporosis

21 January 2018

1 reference

Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism

21 January 2018

1 reference

The Peripheral Metabolism of Parathyroid Hormone

21 January 2018

1 reference

Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis

21 January 2018

1 reference

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

21 January 2018

1 reference

Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis

21 January 2018

1 reference

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

21 January 2018

1 reference

The anabolic effects of parathyroid hormone

21 January 2018

1 reference

Parathyroid hormone for treatment of osteoporosis

21 January 2018

1 reference

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1D353

1 reference

9 August 2017

1 reference